葡萄糖(Dextrose) - 在研适应症：水电解质代谢紊乱，葡萄糖耐受不良，糖尿病前期_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Distal jejunal-release dextrose beads、Glucose、ブドウ糖

+ [7]

靶点-

作用机制-

治疗领域

内分泌与代谢疾病遗传病与畸形其他疾病

在研适应症

水电解质代谢紊乱葡萄糖耐受不良糖尿病前期+ [2]

非在研适应症-

原研机构

Baxter Healthcare Corp.

在研机构

Otsuka Pharmaceutical Factory, Inc.Baxter Healthcare Corp.

湖南嘉恒制药有限公司

+ [4]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (1971-01-25),

水电解质代谢紊乱

最高研发阶段(中国)申请上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C6H14O7

InChIKeyOSNSWKAZFASRNG-UHFFFAOYSA-N

CAS号1258214-35-5

关联

237

项与葡萄糖相关的临床试验

NCT05985135

/ Not yet recruitingN/AIIT

Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People with Type 1 Diabetes Mellitus and Diabetes After Total Pancreatectomy

This research is being done to better understand how insulin effects muscle, blood, and the body in people with Type 1 Diabetes.

开始日期2025-05-01

申办/合作机构

Mayo Clinic

NCT06799715

/ RecruitingN/AIIT

Assessments of Metabolic Responses to Acute Oral Administration of Sucrose, Glucose, and Fructose in Healthy Humans

This project aims to compare the acute metabolic effects of the three sweeteners sucrose, glucose, and fructose on GI hormones (GLP-1, PYY, CCK, and ghrelin).
Furthermore, glycemic control, erythritol and xylitol concentrations, blood coagulation function , blood lipids, uric acid, high-sensitive C-reactive protein (hsCRP), complete blood count, gastric emptying, appetite-related sensations, and GI symptoms will be investigated.

开始日期2025-02-06

申办/合作机构

Universitätsspital Basel

NCT06726980

/ Not yet recruiting临床4期IIT

Effects of Dextrose Versus Saline Infusion on Intrathecal Morphine-Induced Postoperative Nausea and Vomiting During Gynecological Abdominal Surgeries: Randomized Controlled Double-blind Study

Neuraxial anesthesia, which includes epidural anesthesia and intrathecal anesthesia, is a frequent anesthetic approach for cesarean delivery and other lower abdominal and lower limb anesthetic procedures.
Neuraxial morphine (intrathecal or epidural administration) provides high-quality analgesia after gynecological abdominal surgeries.
the aim of the study is to compare the effects of intraoperative infusion of dextrose 5 % and 10 % versus normal saline 0.9 % on the incidence of intrathecal morphine-induced postoperative nausea and vomiting (PONV) in women undergoing gynecological abdominal surgeries. (Neuraxial anesthesia).

开始日期2025-01-01

申办/合作机构

Assiut University

100 项与葡萄糖相关的临床结果

登录后查看更多信息

100 项与葡萄糖相关的转化医学

登录后查看更多信息

100 项与葡萄糖相关的专利（医药）

登录后查看更多信息

5,353

项与葡萄糖相关的文献（医药）

2025-03-01·TALANTA

A highly sensitive flexible sensor based on the MXene/αFe2O3 composite structure applied for the simultaneous detection of glucose and uric acid

Article

作者: Yin, Liang ; Li, Zhaoxin ; Zhang, Wenbo ; Zhang, Haifeng

Sensors based on inorganic nanomaterials for the detection of human body fluids show great potential in real-time detection and treatment of human health due to their advantages of small size and easy to wear. Nevertheless, most of the existing sensors have the disadvantage of detecting relatively simple substances and suffer from low sensitivity, which undermines their practical applicability in body fluids detection. In this study, based on the transition metal carbide (Ti₃C₂T_x, MXene)/αFe₂O₃ grid composite structure, a highly sensitive flexible sensor is proposed, which can realize accurate and simultaneous detection of glucose and uric acid (UA) concentration. The sensor exhibits outstanding durability, enabling it to withstand prolonged immersion in water and exposure to high flow velocities. More importantly, the sensor has extremely high sensitivity for both glucose (2.14 mA mM^-1 cm^-2, 5.5 times the mean value) and UA (2.56 μA μM^-1 cm^-2, 3.5 times the mean value). It also has the advantage of low detection limits (0.27 μM for glucose and 0.31 μM for UA) and a wide linear detection range (1 mM-40 mM for glucose and 10 μM-900 μM for UA) compared to existing sensors for body fluids detection. In addition, the sensor has excellent repeatability, long shelf life (over 40 days) and excellent immunity to interference (accurate detection of glucose and UA in the presence of multiple metal ions as well as organics in human body fluids). This study establishes the groundwork for developing a production-ready and highly sensitive blood detection sensor capable of real-time monitoring.

2025-03-01·MICROBIOLOGICAL RESEARCH

Antimicrobial effect of sulconazole in combination with glucose/trehalose against carbapenem-resistant hypervirulent Klebsiella pneumoniae persisters

Article

作者: Chen, Sheng ; Heng, Heng ; Xie, Miaomiao ; Chen, Kaichao ; Chan, Edward Wai-Chi

The emergence and rapid dissemination of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) pose a serious threat to public health. Antibiotic treatment failure of K. pneumoniae infections has been largely attributed to acquisition of antibiotic resistance and bacterial biofilm caused by the presence of antibiotic persisters. There is an urgent need for novel antimicrobial agents or therapy strategies to manage infections caused by these notorious pathogens. In this study, we screened a collection of compounds that can dissipate bacterial proton motive force (PMF) and intermediate metabolites that can suppress antibiotic tolerance, and identified an antifungal drug sulconazole which can act in combination with glucose or trehalose to exert strong antibacterial effect against starvation-induced CR-hvKP persisters. Investigation of underlying mechanisms showed that sulconazole alone caused dissipation of transmembrane PMF, and sulconazole used in combination with glucose or trehalose could significantly inhibit the efflux activity, reduce NADH and ATP levels, and cause intracellular accumulation of reactive oxygen species (ROS) in CR-hvKP persisters, eventually resulting in bacterial cell death. These findings suggest that the sulconazole and glucose/trehalose combination is highly effective in eradicating multidrug-resistant and hypervirulent K. pneumoniae persisters, and may be used in development of a feasible strategy for treatment of chronic and recurrent K. pneumoniae infections.

2025-03-01·ACTA PAEDIATRICA

EBNEO commentary: Dextrose gel prophylaxis for neonatal hypoglycemia and neurocognitive function at an early school age: A randomised dosage trial

Article

作者: Dinu, Daniela ; Itriago, Elena ; Smith‐Patel, Ashlee

126

项与葡萄糖相关的新闻（医药）

2025-02-11

·健识局

集采中选药物出现大量“0配送”，药企为何摆烂？

2月11日，广州公共资源交易中心发布《各批次集采中选药品合同签订和供应情况的通知》，其中提到，目前各批次集采药品中仍有部分中选药品未及时建立配送关系，或存在合同签订率或者供应率较低等情况。文件显示，一千余个品规药物集采中选后未建立配送关系；205个品规的药物配送率低于30%，其中超七成为0配送。十余家企业合同根本没有签订合同。按照规定，自通知发布之日起7个工作日内仍未建立配送关系、签订合同或恢复正常供应的，这些企业将可能按照信用评价等相关规定受到处罚。集采中选后药物的落地已经是个老生常谈的问题了，广州每个月都会发布公告督促中选企业及时建立建立配送关系、签订合同。即便如此，有一些药企仍然没有重视这个问题，连续多个月被“点名”。在集采时积极报价参与竞争的部分药企，真到了落地执行的时候却直接“摆烂”了。广东月月通报，效果显著在集采这件事上广东的表现相当积极。除了国家集采、省内集采之外，广东还牵头组织过替硝唑等药品、阿比特龙联盟、双氯芬酸联盟等多项集中采购，都曾引发过行业震动。集采品种多了，广东在执行上也花费了更多的心思。为了监督集采品种的落地情况，广东每个月都会发公告统计集采中选药的合同签订以及配送情况，以督促中选企业及时建立建立配送关系、签订合同。健识局整理发现，截止1月31日，广东中选药品合同签订率比较低的企业只有17家。在一年前，这一数字高达91家。截止1月31日，广东共通报了205种品规药物实际供货不合格，其中147种配送率为0，压根没有送货。不过一个变化是，去年同期配送率较低的企业还不乏赛诺菲、诺和诺德、通化东宝等大药企。到了今年，上榜的大部分都是中小规模企业。此外，集采中选产品配送率低于30%的主要是广东组织的联盟集采，国家集采药品占比不到5%。不过，仍有一些企业被多次提名却没有改变。比如，哈三联两种规格的米氮平片，在2024年12月通知就被提到合同签订率为0。如今两个月过去，哈三联并没有做出整改，在最新的公告中仍然为0。值得一提的是，针对同一品种不同品规，药企选取一个主力供货的现象仍然存在。比如，在1月通知中，乐普制药的阿托伐他汀钙片10mg和20mg规格合同签订率均较低。在2月的公告中，乐普制药放弃了20mg规格，合同签订率从20%跌至0，10mg规格的已正常签订合同。上海金不换制药的盐酸异丙嗪放弃了12.5mg规格保住了25mg规格。至于中选药品未建立配送关系的仍然不少。集采招标还需理性参与无论是没有建立配送关系，还是合同签订率、配送率不达标，本质上都是对集采中选结果执行不彻底的表现，也是对契约精神的违背。从广州发布的断供的品规来看，不少是甲硝唑片、阿卡波糖片硝苯地平片等销量大的常用药，以及盐酸氨溴索注射液、葡萄糖、氯化钠注射液等临床常见注射剂品种。有业内人士认为，中标集采后利润不足可能是企业选择断供的原因之一。一些企业为了在集采中抢占身位，当时报价过低导致自己没有利润甚至赔钱。最终没办法按协议供应约定采购量，不再向医疗机构供货。国家层面一直高度重视集采药品的保障供应问题。2024年1月12日,国家医保局在《关于加强医药集中带量采购中选产品供应保障工作的通知》，对中选后长期不签合同，导致医疗机构无法开展采购、影响临床使用的，应视情节取消相关企业中选资格或按规定给予医药价格和招采失信评级。如今的集采药结算条件已经大大改善。2025年1月1日起，海南、广西等9省推进医保基金与医药企业直接结算，医药企业回款周期从平均6个月减少为不到30天。集采中标企业、配送企业、医疗机构一旦完成三方合同签订，医保部门将直接打款60%，合同量执行超过50%支付剩下40%。这也提醒相关企业，需要充分认识集采保供的重要性，对集采药落地等各方面都做好充分的准备，在招标时就理性参与、谨慎报价，一旦中标后必须积极接受中选产品的生产、供应。撰稿丨方涛之编辑丨江芸贾亭运营｜廿十三插图｜视觉中国声明：健识局原创内容，未经许可请勿转载买华为智能手表能刷医保卡？多地已叫停 6600万元工程欠款，压垮老牌中药企业新事丨因美纳回应“不可靠实体清单”：反对任何限制竞争的行为

带量采购

2025-02-10

·摩熵医药

科伦拿下24亿重磅抗菌注射剂，第8款粉液双室袋迎来首过评！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。近日，据NMPA官网最新显示，湖南科伦制药提交的4类仿制药注射用亚胺培南西司他丁钠/氯化钠注射液（规格：1.0g/100ml）获批上市并视同通过一致性评价。该产品适用于多种病原体感染、需氧和厌氧菌混合感染及在病原菌未确定前的早期治疗。截图来源：NMPA 亚胺培南是首个临床应用的碳青霉烯类β-内酰胺抗菌药，其复方制剂自1985年德国上市已有40年历史。国内首创的即配型粉液双室袋亚胺培南西司他丁/氯化钠注射液，因即配即用、高效安全，能有效满足急危重症感染患者的抗感染治疗需求。近年来注射用亚胺培南西司他丁钠在院内销售额均在24亿元左右，其中默沙东占据市场份额近8成。截图来源：摩熵医药全国医院销售数据库目前，亚胺培南西司他丁钠相关品种已有山东新时代药业、深圳市海滨制药、国药集团国瑞药业等6家药企的过评，科伦药业则是首家过评注射用亚胺培南西司他丁钠/氯化钠注射液的企业。截图来源：摩熵医药过评药品汇总数据库科伦长期以来深耕抗感染领域，产品布局覆盖抗病毒、抗真菌、抗细菌等多个领域，目前已有系列抗感染产品获批或通过一致性评价。在高端抗感染领域有注射用头孢他啶阿维巴坦钠/氯化钠注射液、注射用头孢他啶阿维巴坦钠、泊沙康唑肠溶片、泊沙康唑口服混悬液、泊沙康唑注射液等产品获批上市。2025年至今，科伦（含子公司）已有他克莫司缓释胶囊、氯维地平乳状注射液、碘普罗胺注射液等12款品种过评。截图来源：摩熵医药过评药品汇总数据库此外，科伦已有注射用美罗培南/氯化钠注射液、注射用头孢呋辛钠/氯化钠注射液、注射用头孢他啶/5%葡萄糖注射液、注射用头孢曲松钠/氯化钠注射液、注射用头孢西丁钠/葡萄糖注射液、注射用头孢美唑钠/氯化钠注射液、注射用头孢他啶阿维巴坦钠/氯化钠注射液、注射用亚胺培南西司他丁钠/氯化钠注射液8款粉液双室袋品种获批上市，是该领域的领军企业。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

一致性评价上市批准

2024-12-19

·GlobeNewswire-Health Care

Aphaia Pharma to Participate in Panel Discussion at the 1st Annual BioPharma Obesity Innovation Forum in San Francisco

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 1st Annual BioPharma Obesity Innovation Forum, taking place January 11, 2025, in San Francisco, California. The Company is also attending the 43rd Annual J. P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, and is accepting one-on-one meetings. Details on the presentation are as follows: Panel: Obesity, Cardiovascular & Metabolic Diseases PlatformsDate: Saturday, January 11, 2025, at 12:10 p.m. PSTLocation: Marines’ Memorial Club About Sachs 1st Annual BioPharma Obesity Innovation Forum (BOIF)The BOIF, organized by Sachs Associates, will feature over 7 hours of high-level keynotes, panel discussions, and corporate presentations covering all aspects of the bio-pharma obesity science and market, including drug development and technology, as well as highlighting investment opportunities. The sessions will be made available on demand for the virtual audience the week after the JP Morgan meeting. This forum will also set the stage for Sachs’ first obesity focused European event, scheduled for June 17-19, 2025, in Leipzig. About Aphaia PharmaAphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead oral candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. A recently completed Phase 2 trial provided proof-of-concept for its clinical efficacy, demonstrating that the formulation improves glucose tolerance in individuals with prediabetes. APH-012 is currently being evaluated in a Phase 2 trial for chronic weight management in individuals with obesity. The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns. Aphaia Investor ContactGünter JuchoChief Financial Officerjucho@aphaiapharma.com Media ContactMadelin HawtinLifeSci CommunicationsAphaiaPharma@lifescicomms.com

临床2期

100 项与葡萄糖相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02325	葡萄糖	-	DB09341

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
水电解质代谢紊乱	美国	Baxter Healthcare Corp.	1971-01-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
葡萄糖耐受不良	临床2期	斯洛伐克	-	2023-03-31
糖尿病前期	临床2期	斯洛伐克	-	2023-03-31
肥胖	临床2期	格鲁吉亚	-	2022-11-01
肥胖	临床2期	德国	-	2022-11-01
肥胖	临床2期	波多黎各	-	2022-11-01
糖原贮积病	临床申请批准	中国	北京科信必成医药科技发展有限公司	2025-01-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05803772 (GlobeNewswire) 人工标引	临床2期	糖尿病前期	-	APHD-012	簾網襯遞鹹淵襯製選蓋(顧簾衊範糧積鬱選膚憲) = In a group of healthy, prediabetic and diabetic patients, APHD-012 (6 weeks treatment) reduced OGTT blood glucose levels at 120 minutes post-challenge from 9.00.6 to 7.90.6 mmol/L (n=23, p=0.01); placebo treatment in the same patients had no significant effect (8.80.4 mmol/L versus 8.50.6 mmol/L; p=0.33) 網膚齋淵願構憲淵夢艱 (構鑰選範製積觸齋餘襯 ) 更多	积极	2024-06-20
				placebo
ATS2024	N/A	失盐型肾上腺皮质综合症	-	Scheduled insulin therapy	襯選遞憲齋艱艱簾窪繭(鏇衊網糧憲窪選壓製鹹) = revealed central pontine T2 prolongation suggesting osmotic demyelination syndrome with no other abnormalities 膚餘廠觸網醖製鏇醖糧 (壓鹹齋製繭顧築範夢憲 ) 更多	-	2024-05-19
NCT01369147 (CTgov)	临床2期	危重病	12	Enteral feeding+Propofol+Clevidipine+Dextrose-containing IV Fluids (Parenteral Nutrition Energy Dose at 0.6 x Measured REE)	願憲構醖衊齋遞願鑰願(鑰齋憲壓觸簾遞衊網觸) = 齋憲艱範艱鹽襯窪壓築衊範範築艱醖積鏇網觸 (鏇廠觸襯鬱襯醖壓膚願, 醖選願選淵餘醖衊築衊 ~ 築廠鬱壓壓簾範遞鹹鑰) 更多	-	2022-06-10
				Enteral feeding+Propofol+Clevidipine+Dextrose-containing IV Fluids (Parenteral Nutrition Energy Dose at 1.0 x Measured REE)	願憲構醖衊齋遞願鑰願(鑰齋憲壓觸簾遞衊網觸) = 糧醖鹽淵鏇構鑰艱蓋願衊範範築艱醖積鏇網觸 (鏇廠觸襯鬱襯醖壓膚願, 醖淵獵觸齋簾築觸繭醖 ~ 網衊廠獵襯選獵憲積艱) 更多
ATS2022	N/A	乳酸性酸中毒	-	Diazoxide	獵鏇顧獵鑰蓋廠簾觸鑰(廠齋築顧選鹽淵網遞蓋) = severe lactic acidosis following high dextrose infusion in a patient with an insulinoma 鑰鬱廠鹽積觸蓋製壓遞 (窪繭鏇膚艱夢醖窪製鹽 )	-	2022-05-15
				Dextrose infusion
ERA2022	N/A	-	108	4.25% Peritoneal Equilibration Test (PET-4.25%)	糧憲製壓簾鹽廠繭廠醖(襯壓蓋齋製壓淵繭蓋鹽) = 築遞鹹蓋構艱鬱廠網蓋鏇簾淵遞鹽簾淵襯衊廠 (繭獵製壓積壓憲製窪範, 0.27) 更多	积极	2022-05-03
ADA2021	N/A	低血糖	10	Glucose	築餘獵遞餘衊積顧觸製(衊蓋構餘淵獵窪壓鹹鹹) = 簾糧衊廠構築膚壓齋選顧鹽網鏇蓋獵衊網鏇廠 (鑰齋餘簾範簾觸顧獵獵 ) 更多	-	2021-06-01
ENDO2021	N/A	先天性高胰岛素血症 PIK3CA gene	-	Diazoxide	衊網鏇積衊夢壓蓋鬱廠(淵醖願壓壓窪積觸網顧) = 醖鹽糧簾衊鑰齋齋繭範鹹夢糧築範築積觸蓋膚 (夢鏇蓋廠鹽顧廠獵淵艱 ) 更多	-	2021-05-03
				Octreotide	衊網鏇積衊夢壓蓋鬱廠(淵醖願壓壓窪積觸網顧) = 獵壓壓鏇積鹽窪製壓膚鹹夢糧築範築積觸蓋膚 (夢鏇蓋廠鹽顧廠獵淵艱 ) 更多
GLOW (NAASO2020)	N/A	fasting plasma glucose \| fasting plasma insulin \| HOMA-IR ... 更多	436	Gelesis100	範淵鬱鹹構築襯憲築願(齋顧襯遞壓選鑰鹽淵簾): mean difference = 0.1 (95% CI, 0.02 ~ 0.17), P-Value = 0.011	-	2020-11-04
				Placebo
ASN2019	N/A	高钾血症	142	Intravenous Insulin and Dextrose 50%	製艱製齋夢艱憲鏇壓憲(醖憲鏇齋繭鏇夢鏇夢醖) = 積齋鑰艱憲獵繭簾壓夢製製範顧範糧齋膚艱鑰 (壓襯觸糧淵齋憲淵範繭, 1.67 ~ 16.0) 更多	积极	2019-11-05
ERA2019	N/A	HOMA-IR \| BMI	35	intravenous glucose injection (Diabetic patients)	淵顧製襯膚蓋膚繭鬱憲(廠製顧範顧構艱淵夢蓋) = 壓積願襯選簾鹹醖鏇齋餘鬱網範鬱鏇獵觸繭糧 (遞膚網觸襯願衊壓簾鏇 )	积极	2019-06-13